1,016 reports of this reaction
2.0% of all CANAGLIFLOZIN reports
#10 most reported adverse reaction
URINARY TRACT INFECTION is the #10 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,016 FDA adverse event reports linking CANAGLIFLOZIN to URINARY TRACT INFECTION. This represents approximately 2.0% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience urinary tract infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
URINARY TRACT INFECTION is a less commonly reported adverse event for CANAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to urinary tract infection, the following adverse reactions have been reported for CANAGLIFLOZIN:
The following drugs have also been linked to urinary tract infection in FDA adverse event reports:
URINARY TRACT INFECTION has been reported as an adverse event in 1,016 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
URINARY TRACT INFECTION accounts for approximately 2.0% of all adverse event reports for CANAGLIFLOZIN, making it a notable side effect.
If you experience urinary tract infection while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.